Efferocytosis and Genomic Polymorphism in Autoimmune Diseases
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Over the past few years, growing evidences revealed that clearance of apoptotic cells by phagocytosis can result in powerful anti-inflammatory and immunosuppressive effects. In vivo, apoptotic cells are cleared rapidly by neighboring cells, macrophages and related scavengers. Defective clearance of apoptotic cells has been linked closely to autoimmunity and persistent inflammatory disease. Several phagocytic receptors, bridging molecules produced by phagocytes and 'eat-me' signals on apoptotic cells are coordinately involved in mediating clearance of apoptotic cells. Complement receptors (CR3, CR4), collection, CD14, CD36 (Class B scavenger receptor), class A scavenger receptor, asialoprotein receptor, Mer receptor kinase were reported to recognize apoptotic cells. The best characterized system for clearance of apoptotic cells is the recognition of phosphatidylserine (PS) on apoptotic cells by phosphatidylserine receptor (PSR). Milk fat globule- epidermal growth factor 8 (MFG-E8) is an opsonin that bridges phagocytes (by interacting with α vβ3, αvβ5 integrins via RGD motif) and apoptotic cells (by binding PS through Factor V/VIII-C domain). Activated macrophages produce and secret MFG-E8. MFG-E8 is a critical component in PSR-mediated phagocytosis of apoptotic cells. The dominant negative mutant MFG-E8, D89E, that carried a mutated RGD motif inhibited phagocytosis of apoptotic cells in vitro. Injection of D89E into wild type mice induced autoantibodies and IgG deposition on glomeruli. Macrophages from MFG-E8 deficiency (MFG-E8-/-) mice were impaired in engulfment of apoptotic cells, which can be restored by adding recombinant MFG-E8. The female MFG-E8-/- mice spontaneously produced high titer of autoantibodies and developed lupus-like glomerulonephritis at the age of week 40. Defective clearance of apoptotic cells is closely related to development of autoimmunity. In the past 4 years, a growing number of molecules were recognized as receptors for the PS exposed on the apoptotic cells. These molecules were capable of mediating phagocytic clearance, rendering anti-inflammatory cytokines in the phagocytes, and modulating T cell responses.
The specific aim of this proposal is to study genetic polymorphism in MFG-E8, PSR and other factors implicated in phagocytic clearance of apoptotic cells among Taiwanese. By comparing the polymorphism between patients with autoimmune disease (SLE or RA) and healthy control subjects, we will investigate if genetic variations among individuals of genes encoding proteins involved in clearance of apoptotic cells contribute to the pathogenesis of systemic autoimmune diseases SLE and RA.
| Condition |
|---|
|
SLE Rheumatoid Arthritis Healthy Subjects |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Retrospective |
| Official Title: | Efferocytosis (Clearance of Apoptotic Cells by Phagocytosis) and Autoimmune Diseases in Human |
| Estimated Enrollment: | 450 |
| Study Start Date: | January 2006 |
| Estimated Study Completion Date: | July 2012 |
| Estimated Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Taiwan autoimmune diseases case control study
Inclusion Criteria:
- SLE, RA, healthy
Exclusion Criteria:
- nil
Contacts and Locations| Contact: Chung-Yi Hu, PhD | 886-2-2312-3456 ext 66914 | jcyhu@ntu.edu.tw |
| Contact: Ping-Ning Hsu, PhD | 886-2-23123456 ext 88635 | phsu8635@ntu.edu.tw |
| Taiwan | |
| Chung-Yi Hu | Recruiting |
| Taipei, Taiwan, Taiwan, 100 | |
| Contact: Chung-Yi Hu, PhD 886-2-23123456 ext 66914 jcyhu@ntu.edu.tw | |
| Contact: Ping-Ning Hsu, PhD 886-2-23123456 ext 88635 phsu8635@ntu.edu.tw | |
| Principal Investigator: Chung-Yi Hu, PhD | |
| Principal Investigator: | Chung-Yi Hu, PhD | Department of Clinical Laboratory Sciences and Medical Biotechnology |
More Information
No publications provided
| Responsible Party: | National Taiwan University Hospital research ethics committee, National Taiwan University Hospital |
| ClinicalTrials.gov Identifier: | NCT00364728 History of Changes |
| Other Study ID Numbers: | 9561701025, NSC98-2320-B-002-021-MY2 |
| Study First Received: | August 15, 2006 |
| Last Updated: | May 20, 2010 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Autoimmune Diseases Joint Diseases |
Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013